Hidehito HORINOUCHI
@HHorinouchi
Medical Oncologist, NCC Japan, Lung Cancer Study Group @JCOG_official, Education committee @JSMO_official @JLCS_OFFICIAL @IASLC @ASCO FCOI http://bit.ly/3DBhVGE
I am truly humbled by the trust of ESMO members. Thank you all for your support! and warm congratulations to all my colleagues Martin, Nicoletta, Ulrik, and Hope, @MartinReck2 @ulassen @hoperugo Eager to start walking this path together to shape the future of our Society @myESMO
ESMO announces the 2025 election results for the Director positions & the Nomination Committee. Thank you to all #ESMOMembers who voted & contributed to shaping the Society’s future direction 📢Curious to see who was elected? 🔗Read the full announcement ow.ly/fJgs50W92CJ
Tagrisso plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer. Learn more about FLAURA2 👉 clin.larvol.com/trial-detail/N… #LARVOL #CancerResearch #Oncology #ClinicalTrials #CancerData…
🔥🚨Hot Off the Press #BigNews Press Release by @AstraZeneca ⭐️#FLAURA2 trial of #Osimertinib + #Chemotherapy vs #Osimertinib in 1st line Tx for patients with #EGFR+ advanced #LungCancer (#NSCLC) shows: ✅Statistically Significant & Clinically Meaningful Improvement in…
News From Industry/ FLAURA2 Update Source AstraZeneca buff.ly/IxqmQjH Long-term follow-up from the Phase III FLAURA2 trial confirms that combining osimertinib with platinum-based chemotherapy and pemetrexed significantly improves overall survival in patients with…
🔥BREAKING🆙 Positive OS‼️ ✅FLAURA2: Osimertinib + Chemo vs Osimertinib 🎯"Statistically significant and clinically meaningful improvement in the key secondary endpoint of OS" 🗣️@AstraZeneca @OncoAlert @Larvol #EGFR @EGFRResisters astrazeneca.com/media-centre/p…
PL03.13 Osimertinib With/Without Platinum-Based Chemotherapy as 1st-line Treatment in Pts with EGFRm Advanced NSCLC (FLAURA2) by Prof. Pasi Janne. Very important but huge space open for discussion. We need mature PFS2 and OS to discuss with pts. #LCSM #WCLC23 @IASLC @OncoAlert
🚨 There's still time to submit your abstract for #ACLC2025! 🗓️ New deadline: July 18 Submit your research and join us in Ho Chi Minh City, Vietnam, October 9-11. 🔗 bit.ly/44JZHzQ #IASLC #LungCancer #Oncology #CallForAbstracts #CancerResearch
@IASLC - World Conference on Lung Cancer (WCLC) 2025: Expected Dates for Title and Abstract Releases Announced Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #CancerResearch #Oncology #LungCancer #WCLC25…
🟣 Most active cancer institutes on X in Q2 2025, based on oncologists' posts and views. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #ClinicalTrials #OncologyInsights #CancerData…
Honored and humbled to accept a new role as Division Chief for Hematology & Oncology at Georgetown starting next month. Excited for all that the future holds for @Georgetown @LombardiCancer with the best colleagues one could ask for.
💡Starting out in thoracic oncology? The @IASLC Communications Committee proudly brings you: ‘50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic’ A whistlestop tour of key advances, distilled by global leaders @JTOonline @OncoAlert #LCSM jto.org/article/S1556-…
.@charlesrudin shared promising DeLLphi-304 trial data on tarlatamab at #ASCO25. 🔗 Full highlights in ILCN: bit.ly/4leYUxC #LCSM
Top 10 #LungCancer Oncologists for June 2025, curated by @Larvol CLIN. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights | @StephenVLiu | @HHorinouchi |…
Top 10 #LungCancer Trials for June 2025, curated by @Larvol CLIN based on oncologist sentiment on X. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights |…
🌍 Join the global lung cancer community at #WCLC25 in Barcelona, Sept 6–9! 🔬 Cutting-edge science, global networking & expert insights. 🎟️ Register now & save: wclc.iaslc.org #LungCancer #Oncology #IASLC #MedicalConference
Tomorrow is the #SITC Summit on the Future of Neoadjuvant Clinical Trial Design, which will discuss the recent advances in clinical trials for resectable tumors. The Neoadjuvant Clinical Trial Design Working Group is chaired by Patrick Forde, MD. Register: sitcancer.org/neoadjuvant-vs
🌍 Clinicians & those with lived experience in thoracic cancer care: help improve tobacco dependency services. The AIRSPACE Study survey is now in English, Spanish, Japanese & Mandarin! 🕒 15–20 mins 🔒 🎁 Complete by July 2 to win #WCLC25 reg! 👉 bit.ly/IASLCAirspace…
Amazing talk by @UmbertoMalapel1 @isliquidbiopsy taking us through the development of #liquidbiopsies from its infancy not too long ago to what the potentials can soon be! #HKIOF25 @hkumed #LCSM #hongkong 🇭🇰
Big news from @JTOonline! 📘 JTO Impact Factor: 20.8 🔹 #3 in Respiratory Medicine 🔹 #13 in Oncology A high-impact leader in thoracic oncology! 👏 for JTO CRR with an IF of 3.5, rising in both oncology & respiratory rankings! ➡️ bit.ly/3ZGbIol
Join us @IASLC on 6/27 to discuss a few of the most exciting lung cancer studies presented at #ASCO25 All data presented by primary authors of their papers, so a chance to ask all your unanswered questions in the Q&A! @LuisRaezMD @g_mountzios @FordePatrick Dr. Rotow Dr. Chaft
Curious about highlights from #ASCO25? Join us on June 27 for the latest on NSCLC & SCLC breakthroughs, neoadjuvant immunotherapy, EGFR strategies & more. 🎓 1 CME credit available. 👉 Register: bit.ly/25ASCOHighligh… #ASCO25 #LungCancer #CME #Oncology #LCWEBINARS
Curious about highlights from #ASCO25? Join us on June 27 for the latest on NSCLC & SCLC breakthroughs, neoadjuvant immunotherapy, EGFR strategies & more. 🎓 1 CME credit available. 👉 Register: bit.ly/25ASCOHighligh… #ASCO25 #LungCancer #CME #Oncology #LCWEBINARS